Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study
about
Interventions for Old World cutaneous leishmaniasisCurrent challenges in treatment options for visceral leishmaniasis in India: a public health perspectiveTreatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trialA curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapyHigh content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discoveryShort- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.Treatment of visceral leishmaniasis.Liposomal amphotericin B and leishmaniasis: dose and responseActivity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovaniEffectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies.Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.Treatment of visceral leishmaniasis: a review of current treatment practices.Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guideLiposomal amphotericin B: clinical experience and perspectives.Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.Optimizing efficacy of amphotericin B through nanomodification.Therapeutic options for visceral leishmaniasis.Drug resistance in visceral leishmaniasis.The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.Drug delivery strategies for therapy of visceral leishmaniasis.Modes of action of Leishmanicidal antimicrobial peptides.Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.Kala-azar associated with coombs-positive autoimmune hemolytic anemia in the patients coming from the endemic area of this disease and successful treatment of these patients with liposomal amphotericin B.Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health.Interventions for Old World cutaneous leishmaniasis.Chemotherapeutics of visceral leishmaniasis: present and future developments.Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
P2860
Q24241245-349093CD-F50D-465E-A63E-BCA37B8128DEQ28073426-D5B290E9-3799-49A9-9785-C72BCEFB027AQ28346660-1FEF4C74-925D-4E1F-9A8B-3CA0B51237DCQ28474921-59558809-0F74-43DF-ABF8-465BDB422AACQ28485997-EDDCE5C8-48B3-46EE-BE00-BCDA00E85887Q33691395-CCA3884C-D924-422D-8800-8D7F266CE309Q33929849-D6628ED8-517A-4F4F-9011-C4017CF40B54Q33929854-AE81C081-B0D2-4C4B-BE5B-34D9FB7AA181Q33976111-1DA96699-2712-4355-B728-399B8E34AC98Q34024866-B9BBECEE-5D7F-4DDD-B0E0-F9D522595BCBQ34156124-6E56AD91-9256-4420-95F0-C4ACB64F10F8Q34328882-E17FC977-9317-48AD-8B43-6C8240E2F5D6Q34768497-0D130A08-3DDD-437A-8A0E-7D3E6B794F29Q35134721-1F88A4FA-C8FA-4F6B-9763-F1A0A36D9B14Q35160905-031C4D49-8F2C-4F64-8385-EC727197CC65Q36140647-0123C582-F011-4068-AF72-BAFDB1B9C698Q36551607-1ED8192B-CBDD-4228-B507-90A7CEABBA04Q36920328-F17B3598-41D6-4C29-B510-25E11ECBB870Q37333942-2015CA3B-390D-44C8-B101-D1FB2DB4FE25Q37407549-EEE54377-C3FE-4C40-8C70-A76DD53A8362Q37425218-72DFA06C-B52C-4342-98A8-246E7A4F5A05Q37702257-28379C5A-0F4A-480C-B8CE-E67F59A8A938Q38041188-F02171A0-C2EA-4C60-8DBC-5C31EADFBE8DQ38904942-F9B0A165-BE61-4A72-95BC-4E73EEC799FAQ40503805-BC79F4AA-1CA3-4225-A92C-409F28E74ACEQ40550975-D06D22A8-13B8-4F42-B226-10E465221F67Q43167558-C2796FF2-93A7-42CF-9F47-566BEA379910Q46250558-0B02B1CD-62AE-4363-919A-657E7F5B0879Q46713325-96F98803-410C-416E-A0C2-B4370059033BQ57166879-E13ED5D3-D571-4E3A-83B5-8F92B3D8C17C
P2860
Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study
description
1996 nî lūn-bûn
@nan
1996 թուականին հրատարակուած գիտական յօդուած
@hyw
1996 թվականին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Comparison of three treatment ...... randomized dose-finding study
@ast
Comparison of three treatment ...... randomized dose-finding study
@en
Comparison of three treatment ...... randomized dose-finding study
@nl
type
label
Comparison of three treatment ...... randomized dose-finding study
@ast
Comparison of three treatment ...... randomized dose-finding study
@en
Comparison of three treatment ...... randomized dose-finding study
@nl
prefLabel
Comparison of three treatment ...... randomized dose-finding study
@ast
Comparison of three treatment ...... randomized dose-finding study
@en
Comparison of three treatment ...... randomized dose-finding study
@nl
P2093
P2860
P1476
Comparison of three treatment ...... randomized dose-finding study
@en
P2093
P2860
P304
P356
10.1016/S0035-9203(96)90271-0
P407
P577
1996-01-01T00:00:00Z